Will Biosimilar Competition And Product-Hopping Save Regeneron’s Eylea Or Cancel Each Other Out?

 
• By Dean Rudge

Biosimilar entrants look to help protect Regeneron’s currently marketed form of Eylea from the US’s new price negotiation law. But it likely hinges on how CMS views the company’s product-hopping plan.

Joe Biden, Democratic Party (Ron Adar/Shutterstock.com)
The IRA, signed by the Biden administration, created the Medicare price negotiation system. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics